Global Wound Biologics Market Trends and Drivers, Restraints, and Opportunities 2018-2024

  • Product Code:
  • Published Date:
    Apr 2019
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Global Wound Biologics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Wound care products are mainly intended for safeguarding timely wound healing and active control of infection. There are many wound products accessible in the market, from over-the-counter to prescription products. Maximum wound care products are topical and are permitted as medical devices, but a few products such as biologics are scrutinized under strict regulatory guidelines. The wound biologics market is very unified at present, with the US, Europe, and Japan collectively accounting for a significant share of the product sales. The principal variables are the regulatory trails essential for obtaining marketing approval, with the US regulatory necessities being very different when compared to most of the other nations. Furthermore, the standard of care fluctuates significantly between industrialized and emerging countries, making it tougher to conduct sufficiently precise clinical trials in a global setting.
Skin substitutes, growth factors, and enzyme-based products are the major types of biologics in the market. Nearly half of the skin substitute market is dominated by the major players in the market. Organogenesis, Molnlycke, and Smith & Nephew are the major players in this segment.
The growth of the market is driven by an increase in aging population, increasing number of people suffering from diabetes, growing acceptance of innovative technologies for complex wound treatment, and rising incidence of chronic wounds. However, the complex regulatory process and the high cost of biologic wound care are hampering the market growth.
Market Analysis: The “Global Wound Biologics Market” is estimated to witness a CAGR of 12.3% during the forecast period 2017–2023. The market is analyzed based on four segments – products, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global wound biologics market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth. In the US, Organogenesis and MiMedx hold nearly half of the skin substitutes market. However, Europe is close to North America with many companies developing advanced technology products. In Germany, Organogenesis and Integra Life Science hold a significant share of the skin substitutes market.
Product Analysis: Skin substitutes, growth factors, and enzyme-based products are the types of wound closure biologics in the market. Skin substitutes is the major segment of the market. MiMedx, Organogenesis, and Smith and Nephew are the key players in the skin substitute market. MiMedx increased its market share from 24.9% in 2015 to 31% in 2016 in the advanced skin substitute market.
Application Analysis: The applications of the wound biologics include chronic wound and acute wound. Acute wound comprises traumatic wound and surgical wound. As the ratio of the surgical wound is higher in comparison with other wound types, the acute wound closure was the major shareholder of the market in 2017. However, the chronic wound is increasing the burden of healthcare expenditure globally. This has increased the demand for innovative products for the treatment, which is expected to experience the fastest growth rate during the forecast period.
Key Players: Organogenesis, Smith & Nephew, MiMedx, and Integra Life Science are the key players in the market. The other prominent players in the market include Pinnacle Transplant, Osiris, Molyncke Health Care, Soluble Systems, Applied Biologics, and Skye Medical.
Competitive Analysis: Many players are using various strategies such as new product launches, clinical trials, market initiatives, high expense on R&D, agreements, joint ventures, acquisitions, and others to increase their footprints in this market. In January 2018, Alliqua BioMedical, Inc. entered a definitive agreement with Celularity, Inc. to acquire all the assets and rights of the company’s advanced biologic wound care business. This added Biovance Amniotic Membrane Allograft, Interfyl Human Connective Tissue Matrix, UltraMist Therapy System, and other therapeutic products to Alliqua’s portfolio. In January 2016, Human Regenerative Technologies, LLC initiated the building process of its new state-of-the-art amniotic and placental tissue matrix research, development, and processing facility worth $12 million in California, US.
Benefits: The report provides complete details about the usage and adoption rate of wound biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Total Addressable Market 13
3.2 Market Definition – Infoholic Research 13
3.3 Segmented Addressable Market 13
3.4 Trends in Wound Care Biologics Market 14
3.5 Related Markets 15
3.5.1 Active Pharmaceutical Ingredients 15
3.5.2 Diabetes Drugs 16
3.5.3 Regenerative Medicine 16
3.5.4 Oncology (Cancer) Drugs 17
4 Market Outlook 18
4.1 Regulatory Outlook 18
4.2 Market Segmentation 19
4.3 Porter 5(Five) Forces 19
4.4 PEST Analysis 20
5 Market Characteristics 21
5.1 Market Dynamics 21
5.1.1 Drivers 22 Increasing aging population 22 Rising incidence of chronic wounds 22 Increasing number of people suffering from diabetes 23 Increasing acceptance of innovative technologies for complex wound treatment 23
5.1.2 Opportunities 24 Increase in healthcare spending 24 Untapped emerging market in developing countries 24
5.1.3 Restraints 24 Complex regulatory process 24 High cost of biologic wound care 25
5.2 DRO – Impact Analysis 26
5.3 Key Stakeholders 27
6 Types: Market Size and Analysis 28
6.1 Overview 28
6.2 Growth Factors 29
6.3 Skin Substitutes 30
6.4 Enzyme-based Products 33
7 Application: Market Size and Analysis 35
7.1 Overview 35
7.2 Chronic Wound 36
7.3 Acute Wound 36
8 End-users: Market Size and Analysis 37
8.1 Overview 37
8.2 Hospitals & Clinics 37
8.3 Ambulatory Surgical Centers 38
9 Regions: Market Size and Analysis 39
9.1 Overview 39
9.2 North America 40
9.2.1 Overview 40
9.2.2 US 41
9.2.3 Canada 42
9.3 Europe 42
9.3.1 Overview 42
9.3.2 UK 44
9.3.3 Germany 44
9.4 Asia Pacific 44
9.4.1 Overview 44
9.4.2 India 45
9.4.3 China 45
9.5 Rest of the World 46
9.5.1 Overview 46
9.5.2 Middle East & Africa 47
9.5.3 Brazil 47
10 Competitive Landscape 49
11 Vendor Profiles 51
11.1 Smith & Nephew, Inc. 51
11.1.1 Overview 51
11.1.2 Geographic Revenue 54
11.1.3 Business Focus 54
11.1.4 SWOT Analysis 55
11.1.5 Business Strategies 55
11.2 Organogenesis Inc. 56
11.2.1 Overview 56
11.2.2 Business Focus 57
11.2.3 SWOT Analysis 57
11.2.4 Business Strategies 58
11.3 MiMedx 58
11.3.1 Overview 58
11.3.2 Business Focus 59
11.3.3 SWOT Analysis 60
11.3.4 Business Strategies 60
11.4 Integra Life Sciences Corp. 61
11.4.1 Overview 61
11.4.2 Geographic Revenue 63
11.4.3 Business Focus 64
11.4.4 SWOT Analysis 64
11.4.5 Business Strategies 65
12 Companies to Watch For 66
12.1 Pinnacle Transplant Technologies 66
12.1.1 Overview 66
12.2 Osiris Therapeutics, Inc. 66
12.2.1 Overview 66
12.2.2 Highlights 67
12.3 Mölnlycke Health Care AB 67
12.3.1 Overview 67
12.4 Soluble Systems, LLC 68
12.4.1 Overview 68
12.4.2 Highlights 68
12.5 Applied Biologics 69
12.5.1 Overview 69
12.6 Skye Biologics 69
12.6.1 Overview 69
Annexure 71
Abbreviations 71

Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Acelity L.P. Inc., BioD LLC, ConvaTec Group plc, Cytori Therapeutics Inc., Intercytex, Macrocure Ltd., Integra LifeSciences, Organogenesis Inc., Smith & Nephew, Molnlycke Health Care, Nuo Therapeutics Inc., Osiris Therapeutics Inc., and Regenerys Ltd.
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports